AdvisorNet Financial Inc Buys 290 Shares of Boston Scientific Co. (NYSE:BSX)

AdvisorNet Financial Inc grew its holdings in Boston Scientific Co. (NYSE:BSXFree Report) by 8.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,539 shares of the medical equipment provider’s stock after acquiring an additional 290 shares during the quarter. AdvisorNet Financial Inc’s holdings in Boston Scientific were worth $205,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Whitaker Myers Wealth Managers LTD. boosted its position in shares of Boston Scientific by 4.6% in the fourth quarter. Whitaker Myers Wealth Managers LTD. now owns 4,093 shares of the medical equipment provider’s stock valued at $237,000 after acquiring an additional 179 shares during the period. Koss Olinger Consulting LLC boosted its position in shares of Boston Scientific by 3.7% in the first quarter. Koss Olinger Consulting LLC now owns 5,322 shares of the medical equipment provider’s stock valued at $266,000 after acquiring an additional 191 shares during the period. Brighton Jones LLC boosted its position in shares of Boston Scientific by 5.4% in the third quarter. Brighton Jones LLC now owns 3,999 shares of the medical equipment provider’s stock valued at $211,000 after acquiring an additional 205 shares during the period. Altfest L J & Co. Inc. boosted its position in shares of Boston Scientific by 1.6% in the third quarter. Altfest L J & Co. Inc. now owns 13,298 shares of the medical equipment provider’s stock valued at $702,000 after acquiring an additional 208 shares during the period. Finally, Lindbrook Capital LLC boosted its position in shares of Boston Scientific by 6.1% in the third quarter. Lindbrook Capital LLC now owns 3,687 shares of the medical equipment provider’s stock valued at $195,000 after acquiring an additional 211 shares during the period. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $67.47 on Wednesday. Boston Scientific Co. has a twelve month low of $48.35 and a twelve month high of $68.92. The firm has a market cap of $99.17 billion, a PE ratio of 63.06, a price-to-earnings-growth ratio of 2.40 and a beta of 0.78. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.82 and a current ratio of 1.32. The business has a fifty day moving average of $65.84 and a 200-day moving average of $58.47.

Boston Scientific (NYSE:BSXGet Free Report) last announced its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.51 by $0.04. Boston Scientific had a return on equity of 15.99% and a net margin of 11.19%. The company had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.59 billion. During the same period last year, the company posted $0.45 earnings per share. On average, equities research analysts predict that Boston Scientific Co. will post 2.25 EPS for the current fiscal year.

Insider Activity

In related news, EVP Jeffrey B. Mirviss sold 15,000 shares of the firm’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $58.40, for a total value of $876,000.00. Following the transaction, the executive vice president now owns 56,588 shares in the company, valued at $3,304,739.20. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, EVP John Bradley Sorenson sold 16,351 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $69.30, for a total value of $1,133,124.30. Following the transaction, the executive vice president now owns 50,638 shares in the company, valued at $3,509,213.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jeffrey B. Mirviss sold 15,000 shares of the firm’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $58.40, for a total value of $876,000.00. Following the completion of the transaction, the executive vice president now owns 56,588 shares in the company, valued at approximately $3,304,739.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 92,811 shares of company stock worth $5,893,070. 0.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

BSX has been the subject of several research reports. TD Cowen increased their price objective on Boston Scientific from $65.00 to $77.00 and gave the company an “outperform” rating in a research report on Thursday, March 7th. Oppenheimer upped their target price on Boston Scientific from $58.00 to $68.00 and gave the company a “market perform” rating in a research note on Thursday, February 1st. Wells Fargo & Company upped their target price on Boston Scientific from $70.00 to $72.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. BTIG Research restated a “buy” rating and issued a $64.00 target price on shares of Boston Scientific in a research note on Friday, December 29th. Finally, Royal Bank of Canada upped their target price on Boston Scientific from $67.00 to $70.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Two analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $66.62.

Read Our Latest Research Report on BSX

Boston Scientific Profile

(Free Report)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Read More

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSXFree Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.